Even while the anticoagulant AF drug Dabigatran (Pradaxa) has been linked to serious and uncontrollable bleeding risks, the pills are still selling at an alarmingly brisk rate. In fact, the pills are said to have brought its manufacturers over a billion in revenue.
Numerous patients have sued drug maker Boehringner Ingelheim over the effects of Dabigatran and the company’s failure to properly warn the public and healthcare professionals of the bleeding risks associated with the pills. Still, those lawsuits have not slowed the pills’ sales, which have reached blockbuster status after only being on the market for two years. So far, Pradaxa made $1.43 billion last year, which makes it one of the most successful drugs in the world now. The label of “blockbuster drug” is lent whenever one brings in $1 billion in sales. However, a drug that seriously harms patients and even proves fatal for others should not be bringing in so much money. It should be recalled or better regulated.
It appears that Pradaxa, which was originally meant to be used as a safer alternative to the mega-popular anticoagulant Warfarin, is still going to keep going strong regardless of the dangers linked to it. Then again, even the dangers linked to Dabigatran can’t quite measure up to the dangers linked with another anticoagulant medication that is scarcely being used anymore expect where all other similar drugs fail. The anticoagulant, of course, is Multaq made by Sanofi-Aventis. Multaq has been linked to serious side effects, including a worsening of the heart condition, liver failure and lung toxicity.
If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.